Yvette Cajigas & Angela Vasaturo, PhD
Director of Product Development at Ultivue, Inc. & Director of Scientific Affairs, Ultivue
Precise and Robust Immune Profiling: Validation of a Flexible Multiplex Immunofluorescence Workflow
1 hour
Relevant for
InSituPlex
Description Though widely recognized that mIF assays have critical implications for clinical translation, validation of mIF staining that allows for flexibility in biomarker selection is a barrier for mIF integration into clinical practice. Join Yvette Cajigas and Angela Vasaturo, experts in assay development and biomarker strategy, and learn about a simple approach to evaluate sensitivity and reproducibility – without sacrificing the flexibility needed to answer biological questions required for evaluating specific treatment options. Take a deep dive into the world of multiplex immunofluorescence and see first-hand how Ultivue’s OmniVUE™ panels use its patented InSituPlex® technology to advance precision therapies in clinical trials.
Key Takeaways
Meet the presenters
Yvette Cajigas:
Yvette Cajigas is Director of Product Development at Ultivue, and is a board-certified histotechnologist with nearly 2 decades of experience in Anatomic Pathology. She has served as a technical lead at clinical academic and contract research pathology laboratories, and has extensive expertise in histologic technique assay development and multispectral digital pathology.
Angela Vasaturo, PhD
Dr. Angela Vasaturo is Director of Scientific Affairs at Ultivue. Prior to Ultivue, Angela was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center. Angela was among the first in Europe to be involved in the development of multiplex IHC and multispectral imaging and analysis of up to six immunofluorescence markers, and today is considered a leading European expert in multiplex IHC techniques, digital pathology, spatial biology, and tissue imaging.
Related Content
Characterizing spatial distribution of immune-cell subsets in Nonalcoholic Steatohepatitis and Primary Sclerosing Cholangitis using a novel 12-plex Ultimapper ® kit
Presented at EASL 2021
Overview of the differences between standard IHC and multiplexed immunofluoresence
Ultivue
Combinatorial Immunotherapy Approaches for Patients with Advanced Solid Tumors
Length: 60 minutes
